What is Rinvoq, and what is it trying to change?
Rinvoq is the brand name for upadacitinib, an oral medicine made by AbbVie that changes JAK–STAT immune signaling throughout the body. That pathway is a supported rationale for studying vitiligo, but the exact JAK effect that explains benefit in one person is not proven. Evidence Evidence
Why this matters
Rinvoq acts throughout the body rather than only where a cream is applied. The current product label documents JAK signaling effects and also says the relevance of inhibiting particular JAK enzymes to effectiveness and safety remains unknown.
Questions for the prescribing specialist
- What goal would a systemic medicine address for me?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What is known versus inferred about how it works in vitiligo?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is Rinvoq approved for vitiligo where I live?
Status depends on where you live. On July 24, 2026, the European Commission authorized Rinvoq for adults and adolescents age 12 years and older with nonsegmental vitiligo who are candidates for systemic therapy. The current US and UK product information reviewed by SteadySkin does not include vitiligo. So use for vitiligo there is off-label unless a newer regulator record says otherwise. Evidence Evidence Evidence
Why this matters
The European Commission record defines the authorized population: adults and adolescents age 12 years and older with nonsegmental vitiligo who are candidates for systemic therapy. The US DailyMed label and UK product information reviewed here list other immune-mediated indications but not vitiligo.
Questions for the prescribing specialist
- Which exact jurisdiction and current label apply to me?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- If use is off-label, what changes about evidence, consent, monitoring, and coverage?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Who was studied, and what were the reported results?
A peer-reviewed randomized phase 2 trial enrolled 185 adults. At the primary week-24 assessment, the facial outcome was statistically supported in two of the three studied Rinvoq groups versus placebo, but not the third. AbbVie later reported week-48 results from two randomized phase 3 studies: Study 1 included 206 people assigned Rinvoq and 102 assigned placebo; Study 2 included 205 and 101. At least 50% improvement in the total-body score occurred in 19.4% versus 5.9% and 21.5% versus 5.9%. At least 75% improvement in the facial score occurred in 25.2% versus 5.9% and 23.4% versus 6.9%. The phase 3 percentages are sponsor-reported topline results, not peer-reviewed findings. Evidence Evidence Evidence
Why this matters
The phase 2 study was peer reviewed; its primary facial assessment was statistically supported in two of three studied Rinvoq groups, but not the third. The phase 3 design was randomized and placebo controlled, but the numerical results reviewed by SteadySkin came from AbbVie’s topline report rather than a full peer-reviewed publication. “Total-body response” here means at least 50% improvement in the total-body score, and “facial response” means at least 75% improvement in the facial score, both at week 48.
Questions for the prescribing specialist
- Which result reflects the face or body area that matters to me?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What did the sponsor report that has not yet been peer reviewed?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What serious risks and monitoring belong in the conversation?
The current US Rinvoq label carries boxed warnings for serious infections, mortality, malignancy, major cardiovascular events, and thrombosis. It lists known hypersensitivity to upadacitinib or an ingredient as a contraindication. The EMA says Rinvoq must not be used with tuberculosis or another serious infection, severe liver problems, or pregnancy. It also describes additional limits when no suitable alternative exists for older adults or people with cardiovascular or cancer risk. Screening, laboratory monitoring, vaccine review, pregnancy and breastfeeding precautions, medicine interactions, and personal infection, cancer, cardiovascular, clotting, and gastrointestinal history belong in specialist care. Evidence Evidence
Why this matters
The US label distinguishes the formal hypersensitivity contraindication from warnings and situations where use should be avoided or is not recommended. The EMA overview lists separate EU restrictions for tuberculosis or another serious infection, severe liver problems, and pregnancy. The safety conversation also requires context for infections, hepatitis, blood counts, liver tests, lipids, skin cancer, immunization, breastfeeding, and drug interactions.
Questions for the prescribing specialist
- Which warning is most relevant to my history?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What screening and follow-up would be required?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What symptoms or results would change or stop the plan?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What practical burden and access barriers should I expect?
Rinvoq is a systemic treatment with continuing screening, laboratory, follow-up, and access burden. EU authorization does not guarantee local availability or reimbursement, and off-label US or UK use may face additional prescribing and coverage barriers. Evidence Evidence Evidence
Why this matters
The burden includes more than taking a pill: screening, lab visits, medicine reconciliation, infection vigilance, follow-up, and a plan for interruptions or changing health all matter. Approval and reimbursement are separate decisions.
Questions for the prescribing specialist
- Who coordinates screening, lab results, refills, and interruptions?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What written coverage rule applies to this exact use?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would I pay if coverage is denied or delayed?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What is known about combining Rinvoq with narrowband UVB?
A registered Viti-Up substudy is evaluating Rinvoq with narrowband UVB in selected inadequate responders, but no combination result was posted when reviewed. Evidence does not yet establish that adding phototherapy improves the benefit–risk balance. Evidence
Why this matters
The registry shows that the question is being studied. That is useful research context, but a study listing is not a positive result and does not supply a combination plan.
Questions for the prescribing specialist
- Is the proposed combination established, off-label, or investigational?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What evidence supports the exact pair rather than each component alone?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Who owns one coordinated plan?Saving keeps this on your device and needs JavaScript, which is off in this browser.
What remains unknown, and how should I use patient stories?
The evidence does not establish equal response across face, hands, feet, or every other body area, and the phase 3 numbers remain sponsor-reported rather than peer reviewed. Patient stories may reveal burden and priorities, but they cannot establish effectiveness, safety, or who should take a systemic medicine. Evidence Evidence Evidence
Why this matters
Patient experience can reveal acne, lab burden, access friction, missed work, uncertainty, family concerns, and which questions were hard to answer. Those are meaningful lived realities when they are labelled as experience.
Questions for the prescribing specialist
- What important outcome or body area was not reported?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What would make us reassess whether the burden is worth it?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What are the realistic alternatives, including no active treatment now?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Questions that can change the next decision
- For your specialistIs systemic treatment proportionate to my goal?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your specialistWhich infection, cancer, clotting, cardiovascular, pregnancy, or interaction risks matter most for me?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your specialistWhat is approved where I live, and what would screening and follow-up require?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence snapshot
Peer-reviewed phase 2 evidence and sponsor-reported phase 3 results answer different questions and remain limited to the studied populations and outcomes.
- Phase 2
- Randomized, double-blind, placebo-controlled study of 185 adults.
- Phase 3
- Two randomized studies with 614 adults and adolescents; week-48 numerical results remain sponsor-reported.
- Body sites
- Face and total-body outcomes; no reliable separate estimate for every individual site.
- Combination
- An NB-UVB substudy is registered; no result was posted when reviewed.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
A peer-reviewed randomized phase 2 trial enrolled 185 adults. At the primary week-24 assessment, the facial outcome was statistically supported in two of the three studied Rinvoq groups versus placebo, but not the third. AbbVie later reported week-48 results from two randomized phase 3 studies: Study 1 included 206 people assigned Rinvoq and 102 assigned placebo; Study 2 included 205 and 101. At least 50% improvement in the total-body score occurred in 19.4% versus 5.9% and 21.5% versus 5.9%. At least 75% improvement in the facial score occurred in 25.2% versus 5.9% and 23.4% versus 6.9%. The phase 3 percentages are sponsor-reported topline results, not peer-reviewed findings.
- Age range
- The phase 2 study enrolled adults. The phase 3 program enrolled adults and adolescents.
- Condition subtype
- Nonsegmental vitiligo.
- Severity or extent
- The trials required measurable facial and total-body involvement; the phase 3 population was considered eligible for systemic therapy.
- Sample size
- 185 adults in phase 2 and 614 people across the two phase 3 studies.
- Geography and care setting
- Phase 2 ran at 33 sites in the United States, Canada, France, and Japan.
- Skin tone or phototype
- Not reported
- Race
- Not reported
- Ethnicity
- Not reported
- Body sites
- Facial and total-body outcomes were reported. Separate reliable response estimates for hands, feet, genitals, scalp, or other individual regions were not reported in the reviewed sources.
What that means for this page: These group results apply most directly to people resembling the trial populations. They do not predict response for an individual, establish equal effects by body site, or settle benefit and safety outside the studied population.
The current US Rinvoq label carries boxed warnings for serious infections, mortality, malignancy, major cardiovascular events, and thrombosis. It lists known hypersensitivity to upadacitinib or an ingredient as a contraindication. The EMA says Rinvoq must not be used with tuberculosis or another serious infection, severe liver problems, or pregnancy. It also describes additional limits when no suitable alternative exists for older adults or people with cardiovascular or cancer risk. Screening, laboratory monitoring, vaccine review, pregnancy and breastfeeding precautions, medicine interactions, and personal infection, cancer, cardiovascular, clotting, and gastrointestinal history belong in specialist care.
- Age range
- Not reported
- Condition subtype
- Not reported
- Severity or extent
- Not reported
- Sample size
- Not reported
- Geography and care setting
- Not reported
- Skin tone or phototype
- Not reported
- Race
- Not reported
- Ethnicity
- Not reported
- Body sites
- Not reported
What that means for this page: The current label supplies a general systemic JAK-inhibitor safety boundary. Some boxed-warning evidence comes from another JAK inhibitor in older rheumatoid-arthritis populations with cardiovascular risk. That evidence must not be converted into a vitiligo-specific event rate or a personal risk estimate.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- European Medicines AgencyRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the EMA safety overview, including EU restrictions concerning tuberculosis or another serious infection, severe liver problems, pregnancy, and additional caution when no suitable alternative exists for older adults or people with cardiovascular or cancer risk. It does not calculate personal risk, establish reimbursement, or supply a vitiligo regimen.
What it does not support
The product-information document linked from this page was dated before the July 24, 2026 vitiligo authorization decision and must not be treated as the source of the new vitiligo indication.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for current US labeling but not independent efficacy evidence.
What this source supports
Supports the current US indications and boxed safety information.
What it does not support
Vitiligo is not among the current US indications. The label does not settle a pending application, establish approval elsewhere or create a vitiligo treatment plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- eClinicalMedicine (Passeron T, et al.)Randomized trial · Clinical research, tier 2Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: AbbVie funded the study, and multiple authors were AbbVie employees. The peer-reviewed design and results remain sponsor-linked evidence.
What this source supports
Supports the reported randomized phase 2 design, 185-adult study population, facial and total-body outcomes, continued improvement during follow-up, and reported adverse events.
What it does not support
It does not establish approval, comparative superiority, reliable outcomes for individual hands or feet, long-term safety, or an individual result.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- ClinicalTrials.gov, U.S. National Library of MedicineTrial registry · Supporting research, tier 3Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: ClinicalTrials.gov hosts the record, while AbbVie sponsors the studies and supplies the registered information.
What this source supports
Supports the replicate randomized phase 3 protocol, enrolled population, study status, and the registered exploratory narrowband-UVB substudy. The registry did not post phase 3 result tables or a combination result when reviewed.
What it does not support
Registration is not peer review, regulatory approval, proof that adding phototherapy helps, or a personal treatment plan.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- AbbVieManufacturer document · Manufacturer, tier 4Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: AbbVie manufactures Rinvoq, sponsored the studies, analyzed the results, and issued the release before full peer-reviewed publication.
What this source supports
Supports only AbbVie’s reported Viti-Up enrollment, facial and total-body response percentages, selected adverse-event summary, and sponsor interpretation.
What it does not support
The release is not peer-reviewed trial publication, direct comparison with another treatment, body-site-specific proof for hands or feet, long-term safety evidence, or an individual prediction.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- electronic Medicines Compendium / AbbVie LtdManufacturer document · Manufacturer, tier 4Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The electronic Medicines Compendium hosts company-supplied UK product information. It is useful for current listed indications but is not independent clinical evidence.
What this source supports
Supports that the UK product information reviewed did not list a vitiligo indication.
What it does not support
It does not prove that no later MHRA decision exists or establish status outside the UK.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.